Novartis AG-Product Pipeline Review-2015

Novartis AG-Product Pipeline Review-2015

  • Products Id :- GMDHC07243CDB
  • |
  • Pages: 484
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Novartis AG-Product Pipeline Review-2015


Global Markets Direct's, 'Novartis AG-Product Pipeline Review-2015', provides an overview of the Novartis AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Novartis AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Novartis AG including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Novartis AG's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Novartis AG's pipeline products

Reasons To Buy

Evaluate Novartis AG's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Novartis AG in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Novartis AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Novartis AG and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Novartis AG

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Novartis AG and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Novartis AG Snapshot 8

Novartis AG Overview 8

Key Information 8

Key Facts 8

Novartis AG-Research and Development Overview 9

Key Therapeutic Areas 9

Novartis AG-Pipeline Review 28

Pipeline Products by Stage of Development 28

Pipeline Products-Monotherapy 29

Pipeline Products-Combination Treatment Modalities 30

Pipeline Products-Partnered Products 31

Pipeline Products-Out-Licensed Products 34

Novartis AG-Pipeline Products Glance 36

Novartis AG-Late Stage Pipeline Products 36

Novartis AG-Clinical Stage Pipeline Products 41

Novartis AG-Early Stage Pipeline Products 51

Novartis AG-Unknown Stage Pipeline Products 54

Novartis AG-Drug Profiles 55

(indacaterol maleate + glycopyrrolate) 55

(sacubitril + valsartan) 57

eltrombopag olamine 60

erismodegib 63

EXE-844 66

glycopyrrolate 67

haemophilus influenzae [serotype B] vaccine 69

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine 70

omalizumab 72

panobinostat 74

ruxolitinib phosphate 80

serelaxin 85

trametinib dimethyl sulfoxide 88

imatinib mesylate 91

pazopanib hydrochloride 93

(vildagliptin + metformin hydrochloride) 98

aliskiren fumarate 99

bimagrumab 101

buparlisib hydrochloride 103

canakinumab 107

ceritinib 111

dabrafenib mesylate 114

everolimus 116

EXE-844b 121

fingolimod hydrochloride 122

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine 125

midostaurin 126

nilotinib 128

ofatumumab 131

osilodrostat 136

oxytocin 138

pasireotide 140

pasireotide LAR 143

pradigastat sodium 145

ranibizumab 146

ribociclib 149

seasonal influenza (quadrivalent) vaccine 152

secukinumab 153

siponimod 157

zoledronic acid 159

(VAK-694 + dectrekumab) 161

aldesleukin 162

alpelisib 164

AQW-051 166

BCT-197 167

BGS-649 168

BHQ-880 169

BPS-804 171

BVS-857 172

CAD-106 173

capmatinib 175

CDZ-173 177

CFZ-533 178

cipargamin 179

CJM-112 180

dectrekumab 181

EGF-816 183

FCR-001 184

fevipiprant 186

GSK-2285921 188

HSC-835 190

infigratinib 191

influenza [strain H5N1] vaccine 192

KAF-156 193

KRP-203 194

LCL-161 196

LFF-269 198

LFG-316 199

LFX-453 201

ligelizumab 202

LIK-066 204

LJM-716 205

LMI-070 207

mavoglurant 208

MCS-110 210

NOV-3 211

octreotide acetate long acting 212

QAL-964 214

QBM-076 215

QBW-251 216

seasonal influenza (trivalent) vaccine 217

selurampanel 218

tisagenlecleucel-T 220

VAY-736 222

BPR-277 224

BZF-961 225

CFG-920 226

CGF-166 227

CLR-457 229

CSJ-148 230

FGF-401 231

HDM-201 232

LAG-525 233

lapatinib ditosylate 234

LEZ-763 238

LFA-102 239

LGK-974 240

PDR-001 241

PIM-447 242

RAF-265 243

sotrastaurin acetate 244

ABL-001 246

Cell Therapy to Target c-Met for Cancer 247

Cell Therapy to Target EGFR for Glioblastoma 248

CGM-097 249

huCART19 250

IDH-305 251

influenza [strain A/H3N2] (monovalent) vaccine 252

influenza [strain H7N9] (monovalent) vaccine 253

LEQ-506 254

LHW-090 255

LML-134 256

LOP-628 257

MesoCART 258

NOV-10 260

NOV-7 261

NOV-8 262

NOV-9 263

octreotide acetate LAR 264

PCA-062 266

QCC-374 267

TAP-311 268

Antibody to Inhibit PD-L1 for Cancer 269

Antibody to Inhibit TIM-3 for Cancer 270

AUSRM-057 271

BQS-481 272

BVB-808 273

CART-123 274

Cell Therapy Program for Cancer 275

Cell Therapy to Target 5T4 for Oncology 276

Cell Therapy to Target GD2 for Neuroblastoma 277

cosyntropin ER 278

ESK-1 279

GNFPf-5069 280

HG-78501 281

IMP-701 282

Kartogenin 283

KR-22809 284

LCZ-960 285

LGB-321 286

LQN-725 287

Monoclonal Antibody Conjugated 3 for Cancer 288

Monoclonal Antibody to Inhibit CXCR2 for Respiratory Diseases 289

NIBR-0213 290

NITD-349 291

NITD-916 292

NVPQBE-170 293

NVPTNKS-656 294

Small Molecule to Activate Nurr1 for Multiple Sclerosis 295

Small Molecule to Agonize GPR119 for Type 2 Diabetes 296

Small Molecule to Agonize GPR39 for Type 2 Diabetes 297

Small Molecule to Inhibit LRRK2 for Parkinsons Disease 298

Small Molecule to Inhibit OX2R for Insomnia 299

Small Molecules to Antagonize CSF1R for Cancer and Osteolysis 300

Small Molecules to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes 302

Small Molecules to Inhibit Pan-RAF Kinase for Oncology 303

Antibodies to Inhibit CTLA4 and PD-1 for Cancer 304

ESBA-903 SR 305

LJH-685 306

Small Molecule to Agonize Adrenergic Beta-2 Receptor for COPD 307

Small Molecules 1 for Undisclosed Indication 308

Small Molecules 2 for Undisclosed Indication 309

Small Molecules for Malaria 310

Small Molecules for Rhinovirus Infection 311

Small Molecules for Tuberculosis 312

Small Molecules to Inhibit Acetyl-CoA Carboxylase for Metabolic, Cardiovascular and Infections 313

Small Molecules to Inhibit CFTR for Secretory Diarrhea 314

Small Molecules to Inhibit PI4KIIIbeta for HCV 315

Small Molecules to Inhibit Renin for Hypertension 316

Small Molecules for Mycobacterium Tuberculosis 317

Novartis AG-Pipeline Analysis 318

Novartis AG-Pipeline Products by Target 318

Novartis AG-Pipeline Products by Route of Administration 333

Novartis AG-Pipeline Products by Molecule Type 334

Novartis AG-Pipeline Products by Mechanism of Action 336

Novartis AG-Recent Pipeline Updates 346

Novartis AG-Dormant Projects 430

Novartis AG-Discontinued Pipeline Products 437

Discontinued Pipeline Product Profiles 439

Novartis AG-Company Statement 450

Novartis AG-Locations And Subsidiaries 452

Head Office 452

Other Locations & Subsidiaries 452

Appendix 469

Methodology 469

Coverage 469

Secondary Research 469

Primary Research 469

Expert Panel Validation 469

Contact Us 469

Disclaimer 470

List of Tables

Novartis AG, Key Information 22

Novartis AG, Key Facts 22

Novartis AG-Pipeline by Indication, 2015 24

Novartis AG-Pipeline by Stage of Development, 2015 42

Novartis AG-Monotherapy Products in Pipeline, 2015 43

Novartis AG-Combination Treatment Modalities in Pipeline, 2015 44

Novartis AG-Partnered Products in Pipeline, 2015 45

Novartis AG-Partnered Products/ Combination Treatment Modalities, 2015 46

Novartis AG-Out-Licensed Products in Pipeline, 2015 48

Novartis AG-Out-Licensed Products/ Combination Treatment Modalities, 2015 49

Novartis AG-Pre-Registration, 2015 50

Novartis AG-Filing rejected/Withdrawn, 2015 51

Novartis AG-Phase III, 2015 52

Novartis AG-Phase II, 2015 55

Novartis AG-Phase I, 2015 60

Novartis AG-Preclinical, 2015 65

Novartis AG-Discovery, 2015 67

Novartis AG-Unknown, 2015 68

Novartis AG-Pipeline by Target, 2015 332

Novartis AG-Pipeline by Route of Administration, 2015 347

Novartis AG-Pipeline by Molecule Type, 2015 349

Novartis AG-Pipeline Products by Mechanism of Action, 2015 350

Novartis AG-Recent Pipeline Updates, 2015 360

Novartis AG-Dormant Developmental Projects,2015 444

Novartis AG-Discontinued Pipeline Products, 2015 451

Novartis AG, Subsidiaries 466

List of Figures

Novartis AG-Pipeline by Top 10 Indication, 2015 24

Novartis AG-Pipeline by Stage of Development, 2015 42

Novartis AG-Monotherapy Products in Pipeline, 2015 43

Novartis AG-Combination Treatment Modalities in Pipeline, 2015 44

Novartis AG-Partnered Products in Pipeline, 2015 45

Novartis AG-Out-Licensed Products in Pipeline, 2015 48

Novartis AG-Pipeline by Top 10 Target, 2015 332

Novartis AG-Pipeline by Top 10 Route of Administration, 2015 347

Novartis AG-Pipeline by Top 10 Molecule Type, 2015 348

Novartis AG-Pipeline Products by Top 10 Mechanism of Action, 2015 350

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Novartis AG; Novartis AG - Key Therapeutics; Novartis AG - Pipeline Overview and Promising Molecules; Novartis AG - News; Novartis AG - Latest Updates; Novartis AG - Pipeline; Novartis AG - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101595
Site License
USD 3000 INR 203190
Corporate User License
USD 4500 INR 304785



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]